Details: pack, label wording, sources, registration
Neo-Ferro-Folgamma 114 mg/0.8 mg, Coated tablet
gastro-resistant tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Oral iron replacement for laboratory-confirmed iron-deficiency anaemia after identifying and treating the underlying cause; fixed folate is not independently adequate folate replacement
5.6/10
Weak evidence support
Details →
vetman assessment
Neo-Ferro-Folgamma
×
114 mg/0.8 mg, gastro-resistant tablet, human medicine
Assessed clinical scope Dog · Oral iron replacement for laboratory-confirmed iron-deficiency anaemia after identifying and treating the underlying cause; fixed folate is not independently adequate folate replacement · By mouth
Care setting Veterinarian-directed off-label outpatient treatment with baseline diagnosis, interaction review, serial CBC/reticulocyte and iron-response monitoring, and immediate overdose safeguards.
vetman score
5.6/10
Weak evidence support
Evidence confidence: Low
Georgia: Yes, human · № რ-040151 · Verified on 15 Oct 2026
Off-label use
Traceable human iron/folate tablet with plausible canine iron-replacement value, but no exact veterinary study or defensible calculator dose. Use only after confirming iron deficiency; its folate component neither treats canine folate deficiency adequately nor supplies B12.
Regulatory and scientific credibility 7.0/10
Exact current composition, manufacturer, dosage form and human regulatory identity are traceable, including Georgian human registration; none establishes veterinary approval, target-animal dose or efficacy.
Clinical efficacy 5.5/10
Oral ferrous sulfate has an accepted canine hematinic role and the whole-tablet salt mass can nominally fit a class range, but no exact-product canine outcome/bioavailability study exists, the source does not resolve salt versus elemental mass, and the fixed folate dose is mismatched.
Safety and tolerability 4.5/10
Known oral-iron GI intolerance and mucosal injury, clinically important interactions, diagnostic misuse and potentially severe elemental-iron overdose limit safety. Exact repeated-dose, reproductive and comorbidity safety in dogs is absent.
Clinical practicality 5.5/10
Once-daily whole-tablet administration may be feasible in some dogs, but the unscored gastro-resistant tablet has no validated equal-subdivision or altered-administration instruction; exact dosing is unresolved, treatment is prolonged and serial laboratory monitoring plus interaction spacing are required.
Full-course cost-effectiveness -
A current Georgian exact-pack price and a validated exact-product veterinary course were not verified; cost is excluded from the denominator.
Important safety and use flags
Human gastro-resistant tablet. Georgian and European human registrations do not establish veterinary approval; all dog/cat use is off-label. No exact-product dog/cat dose is established. Merck does not clarify whether its ferrous-sulfate milligrams are salt or elemental mass; do not create a calculator dose or copy a human regimen. Each tablet provides 0.8 mg folic acid but no vitamin B12. This is below separately listed dog/cat folate regimens; do not titrate folate by adding tablets or use it as cobalamin replacement. Confirm iron deficiency and investigate chronic blood loss, parasites, nutrition, malabsorption or other cause before treatment. Folate can improve haematology while unrecognised B12-related neurological injury continues. The gastro-resistant tablet has no score or validated equal-division instruction. Do not assume splitting, crushing or chewing preserves dose accuracy or the enteric presentation; retained/chewed iron tablets can injure oral or oesophageal mucosa. Monitor appetite, vomiting, diarrhoea/constipation, abdominal pain and dark stool, plus CBC/reticulocytes and iron indices. Non-response requires diagnostic reassessment, not automatic dose escalation. Iron overdose is an emergency. Each tablet contains 36.77 mg elemental iron; calculate accidental exposure from elemental iron. More than 50 mg/kg generally warrants decontamination/GI protection and more than 80 mg/kg additional monitoring/treatment. Avoid in iron overload, non-iron-deficiency anaemia and repeated transfusion without proven deficiency. Do not combine with parenteral iron or dimercaprol. Review and appropriately separate antacids, calcium/magnesium, tetracyclines, fluoroquinolones, bisphosphonates, levothyroxine, penicillamine, zinc, cholestyramine and absorption-reducing foods; review anticonvulsants and folate antagonists. Exact long-term, juvenile, pregnancy/lactation and comorbidity safety is not established. Store securely away from animals and children; delayed liver injury can follow an apparently improved overdose phase. Assessment sources +
Close
Cat
Oral iron replacement for laboratory-confirmed iron-deficiency anaemia after identifying and treating the underlying cause; fixed folate is not independently adequate folate replacement
4.5/10
Weak evidence support
Details →
vetman assessment
Neo-Ferro-Folgamma
×
114 mg/0.8 mg, gastro-resistant tablet, human medicine
Assessed clinical scope Cat · Oral iron replacement for laboratory-confirmed iron-deficiency anaemia after identifying and treating the underlying cause; fixed folate is not independently adequate folate replacement · By mouth
Care setting Veterinarian-directed off-label outpatient treatment with baseline diagnosis, interaction review, serial CBC/reticulocyte and iron-response monitoring, and immediate overdose safeguards.
vetman score
4.5/10
Weak evidence support
Evidence confidence: Low
Georgia: Yes, human · № რ-040151 · Verified on 15 Oct 2026
Off-label use
Poorly fitted human fixed combination for cats: no exact feline study, no defensible calculator dose, and the whole tablet is above the nominal ferrous-sulfate range without a validated equal-subdivision instruction. Prefer a veterinarian-selected formulation that permits species-appropriate iron dosing.
Regulatory and scientific credibility 7.0/10
Exact current composition, manufacturer, dosage form and human regulatory identity are traceable, including Georgian human registration; none establishes veterinary approval, target-animal dose or efficacy.
Clinical efficacy 3.5/10
Iron replacement has biological rationale, but no exact-product feline efficacy or pharmacokinetic study exists; the 114 mg whole-tablet salt mass exceeds the nominal feline class range, cannot be accurately divided, and its fixed folate dose is mismatched.
Safety and tolerability 4.0/10
The narrow whole-tablet fit adds to oral-iron GI/mucosal toxicity, interaction and severe overdose risks. Exact feline repeated-dose, reproductive and common-comorbidity safety is absent.
Clinical practicality 3.0/10
The unscored gastro-resistant tablet has no validated equal-subdivision or altered-administration instruction and its whole-unit strength poorly fits the nominal feline range; prolonged administration, interaction spacing and serial laboratory monitoring further reduce practicality.
Full-course cost-effectiveness -
A current Georgian exact-pack price and a validated exact-product veterinary course were not verified; cost is excluded from the denominator.
Important safety and use flags
Human gastro-resistant tablet. Georgian and European human registrations do not establish veterinary approval; all dog/cat use is off-label. No exact-product dog/cat dose is established. Merck does not clarify whether its ferrous-sulfate milligrams are salt or elemental mass; do not create a calculator dose or copy a human regimen. Each tablet provides 0.8 mg folic acid but no vitamin B12. This is below separately listed dog/cat folate regimens; do not titrate folate by adding tablets or use it as cobalamin replacement. Confirm iron deficiency and investigate chronic blood loss, parasites, nutrition, malabsorption or other cause before treatment. Folate can improve haematology while unrecognised B12-related neurological injury continues. The gastro-resistant tablet has no score or validated equal-division instruction. Do not assume splitting, crushing or chewing preserves dose accuracy or the enteric presentation; retained/chewed iron tablets can injure oral or oesophageal mucosa. Monitor appetite, vomiting, diarrhoea/constipation, abdominal pain and dark stool, plus CBC/reticulocytes and iron indices. Non-response requires diagnostic reassessment, not automatic dose escalation. Iron overdose is an emergency. Each tablet contains 36.77 mg elemental iron; calculate accidental exposure from elemental iron. More than 50 mg/kg generally warrants decontamination/GI protection and more than 80 mg/kg additional monitoring/treatment. Avoid in iron overload, non-iron-deficiency anaemia and repeated transfusion without proven deficiency. Do not combine with parenteral iron or dimercaprol. Review and appropriately separate antacids, calcium/magnesium, tetracyclines, fluoroquinolones, bisphosphonates, levothyroxine, penicillamine, zinc, cholestyramine and absorption-reducing foods; review anticonvulsants and folate antagonists. Exact long-term, juvenile, pregnancy/lactation and comorbidity safety is not established. Store securely away from animals and children; delayed liver injury can follow an apparently improved overdose phase. Assessment sources +
Close
Administration route
By mouth
Registration
Georgia
Yes, human
In force until 06 Feb 2029
Human (Ministry of Health, RAMA)
№ რ-040151
Verified on: 15 Oct 2026
EU
Yes, human
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified
Each tablet contains dried ferrous sulfate 114 mg, equivalent to elemental iron 36.77 mg, plus folic acid 0.8 mg. No exact-product dog or cat dose is established. Merck lists ferrous sulfate 100–300 mg/day for dogs and 50–100 mg/day for cats but does not clarify salt versus elemental mass; the 114 mg gastro-resistant tablet has no score or equal-division instruction and exceeds the nominal feline range. Merck folic-acid regimens (dog 5 mg/day; cat 2.5 mg/day for one month) are not matched by this 0.8 mg fixed combination. Do not create a calculator dose or assume that splitting, crushing or chewing preserves dose accuracy and the gastro-resistant presentation.
